{"product_id":"modern-biopharmaceuticals-4-volume-set-isbn-9783527311842","title":"Modern Biopharmaceuticals, 4 Volume Set","description":"The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. \u003cbr\u003e Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years. \u003cbr\u003e \u003cbr\u003e With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade. Volume 1\u003cbr\u003e \u003cbr\u003e INTRODUCTION\u003cbr\u003e PART I: BIOPHARMACEUTICALS USED IN MOLECULAR MEDICINE\u003cbr\u003e Genes \u0026amp; genomes - correlation between genes, diseases \u0026amp; biopharmaceuticals\u003cbr\u003e siRNA - the magic bullet \u0026amp; other gene therapeutical approaches\u003cbr\u003e Mobilis in mobile - human embryonic stem cells \u0026amp; other sources for cell therapy\u003cbr\u003e \u003cbr\u003e \u003cbr\u003e Volume 2\u003cbr\u003e \u003cbr\u003e PART II: BIOPHARMACEUTICALS AND THEIR MODE OF ACTION\u003cbr\u003e The clotting cascade - lysis, coagulation \u0026amp; a fine-tuned balance\u003cbr\u003e Errare humanum est - what causes cancer \u0026amp; how to selectively fight tumors\u003cbr\u003e Mundus vult decipi - high mutation rates of HIV \u0026amp; new paradigms for treatment\u003cbr\u003e PART III: IMPROVING THE DEVELOPMENT OF BIOPHARMACEUTICALS\u003cbr\u003e Citius, altius, fortius - acceleration by high throughput \u0026amp; ultra-HT\u003cbr\u003e Early target validation - knock-out mice \u0026amp; more\u003cbr\u003e Revolution by evolution - rational design for desire \u0026amp; the scientific art of optimization\u003cbr\u003e \u003cbr\u003e \u003cbr\u003e Volume 3\u003cbr\u003e \u003cbr\u003e PART IV: PRODUCTION OF BIOPHARMACEUTICALS\u003cbr\u003e The industry's workhorses - mammalian expression systems\u003cbr\u003e A ripe and blooming market - biopharmaceuticals from transgenic animals \u0026amp; plants\u003cbr\u003e Alea non iacta est - improving established expression systems\u003cbr\u003e When success raises its ugly head - outsourcing to uncork the capacity bottleneck\u003cbr\u003e PART V: BIOPHARMACEUTICALS USED FOR DIAGNOSTICS AND IMAGING\u003cbr\u003e From hunter to craftsman - engineering antibodies with nature's universal toolbox\u003cbr\u003e Find, fight \u0026amp; follow - target-specific troica from Mother Nature's Pharmacopoiea\u003cbr\u003e Getting insight - sense the urgency for early diagnostics\u003cbr\u003e \u003cbr\u003e \u003cbr\u003e Volume 4\u003cbr\u003e \u003cbr\u003e PART VI: ADVANCED APPLICATION ROUTES FOR BIOPHARMACEUTICALS\u003cbr\u003e Getting inside - quest for the best \u0026amp; how to improve delivery\u003cbr\u003e Pathfinder - new ways for peptides, proteins \u0026amp; Co\u003cbr\u003e Via mala - the stony road of DNA delivery: back-pack, feed-back \u0026amp; pay-back\u003cbr\u003e Getting beyond - rocket science \u0026amp; science fiction\u003cbr\u003e PART VII: FROM TRANSCRIPTION TO PRESCRIPTION\u003cbr\u003e Opening the therapeutic window - between systemic toxicity \u0026amp; lack of efficacy\u003cbr\u003e Happy end - claim to fame \u0026amp; approval\u003cbr\u003e PART VIII: FROM BENCH TO BEDSIDE -\u003cbr\u003e THE AFTERMATHS\u003cbr\u003e Think big \u0026amp; dealmaking for growth - global changes in the health-care sector\u003cbr\u003e News \u0026amp; views - quo vadis, biopharmaceuticals?\u003cbr\u003e Small molecules - light at the end of the tunnel or back to the roots? \"... an authoritative sourcebook dealing with the entire broad range of biopharmaceuticals now available. ... an impressive compilation of outstanding results written by brilliant, creative thinkers who are shaping present and future biotechnology. I am pleased to recommend strongly this complete and comprehensive basic reference source for this new, exciting field to biotechnologists, clinicians, physicians, pharmacists, pharmaceutical chemists, molecular biologists, medicinal chemists, and anyone working in the biotechnological and pharmaceutical industries or in medicinal institutes. It should also be invaluable to undergraduate and graduate students, postdoctoral fellows, and researchers looking for quick, clear, and concise ideas on topics that lie outside their areas of expertise. It also belongs in academic, industrial, and governmental libraries.\" (\u003ci\u003eThe Chemical Educator\u003c\/i\u003e)\u003cbr\u003e\u003cbr\u003e\"This is an extensive and unmatched compilation of comprehensive, in-depth current knowledge and history of biopharmaceuticals...the author is commended for this grand effort.\" (\u003ci\u003eVeterinary Pathology\u003c\/i\u003e)\u003cbr\u003e\u003cbr\u003e\"I heartly recommend this authoritative, comprehensive reference to this new, exciting field dealing with the entire broad range of available biopharmaceuticals. It will be invaluable to biotechnologists, clinicians, physicians, pharmacists, pharmaceutical chemists, molecular biologists, medicinal chemists and anyone working in the biotechnological and pharmaceutical industries or in medicinal institutes. It should be also be useful for undergraduate and graduate students, postdoctoral fellows, and researchers seeking quick, clear, and concise ideas on topics outside their areas of specialization. it should also find a place in academic, industrial, and governmental libraries.\" (\u003ci\u003eChemMedChem\u003c\/i\u003e)\u003cbr\u003e\u003cbr\u003e\"All in all, this is an impressive snapshot of the field.\" (\u003ci\u003eJournal of Medicinal Chemistry\u003c\/i\u003e)\u003cbr\u003e\u003cbr\u003e\"... the four volumes represent a highly valuable reference compendium for any practicing scientists interested in this sector of biotechnology.\" (\u003ci\u003eChemistry and Industry\u003c\/i\u003e)\u003cbr\u003e\u003cbr\u003e\"Due to the impressive accumulation of outstanding results, presented by brilliant, privileged and creative thinkers, the book reads like the Who is Who of biotechnology. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel Prize laureates Robert Huber, Thomas R. Cech, and Manfred Eigen as well as authors from the world's most famous academic institutes and biotech companies.\" (\u003ci\u003eBIOforum Europe\u003c\/i\u003e) \"Der Herausgeber Dr. Jörg Knäblein ist der Leiter der Abteilung Mikrobiologische Chemie bei Schering. Das Werk ist eine einzigartige und umfassende Einführung in die neuere technologische Entwicklung bei Biopharmazeutika, es zeigt die Paradigmenwechsel in der medizinischen Behandlung auf und wie diese Veränderungen auf die industrielle Forschung ausstrahlen. Die Autoren des Werkes kommen aus den weltweit renommiertesten Forschungsinstituten - darunter die Nobelpreisträger Robert Huber und Thomas R. Cech - und Biotechnologie-Unternehmen.\" CHEManager\u003cbr\u003e \u003cbr\u003e \"Das Werk umfasst vier Bände mit allein 80-seitigem Executive Summary. Hier wird das heutige Wissen der modernen Wirkstoffentwicklung aus akademischer und Industrieforschung zusammengeführt. Von Antikörper bis Zulassungsverfahren: Methoden, Mechanismen, Genregulation und Gesundheitspolitik werden von ausgewiesenen Spezialisten detailliert auf dem neuesten Stand dargestellt.\" BioRegioN\u003cbr\u003e \u003cbr\u003e \"...ein umfassendes Bild über den aktuellen Stand der biotechnologischen Entwicklung auf der Basis molekularbiologischer Wissenschaften... Die beigefügte CD zum Buch enthält unter anderem einige beeindruckende Darstellungen aus dem Institut von Dr. Hwang ... Ebenfalls sind die kompletten Inhaltsverzeichnisse in jedem Band hilfreich. ... molekularbiologische Strukturen und Abbildungen in hoher Qualität ... Ein umfassendes Werk und Spiegel der derzeit erfolgreichen Pharma-Branche.\" Umwelt und Gesundheit \u003cbr\u003e \u003cbr\u003e \"Vier Bände, 1886 Seiten, 4,5 Kilogramm Lebendgewicht: \"Modern Biopharmaceuticals\" beansprucht, rein optisch gesehen, viel Platz. Inhaltlich ist damit der Anspruch auf Vollständigkeit verbunden. In der Tat decken die Beiträge ein extrem breites Themenspektrum ab, das seinesgleichen sucht...Nicht nur inhaltlich, sondern auch unter formalen Gesichtspunkten kann das Buch punkten. Die einzelnen Kapitel illustrieren die Themen teilweise an instruktiven Fallbeispielen und sind im Detail präzise, ohne sich in Nebensächlichkeiten zu verlieren... Unternehmen, Organisationen und Behörden, die sich im weitesten Sinne mit Biotechnologie und Biopharmazeutika befassen ... investieren sinnvoll ...\" Nachrichten aus der Chemie\u003cbr\u003e \u003cbr\u003e \"Ein wirklich beeindruckendes Werk. Wenn man sich über Wochen mit den vier Bänden beschäftigt und dazu noch die eindrucksvollen Präsentationen und Filme der beiliegenden CD angesehen hat, kommt man zu dem Schluss, dass die zu Beginn zitierten Marketingaussagen absolut zutreffend sind. Dieses Werk ist ein \"Guiness Buch\" der Biotechnologie, von der ersten bis zur letzten Seite spannend und lehrreich, geeignet für den Studenten wie für den Dozenten, für den Grundlagenforscher wie für den Entwickler. Mit nahezu 400 Graphiken gut bebildert, bleibt neben der hohen Informationsdichte auch immer Platz für die didaktischen Ansätze. Es ist zu hoffen und zu erwarten, dass diese vier Bände über Design, Entwicklung und Optimierung von modernen biopharmazeutischen Produkten in den wissenschaftlichen Instituten und den Büros der pharmazeutischen und biotechnologischen Industrie Einzug halten werden.\"\u003cbr\u003e Arzneimittel-Forschung \/ Drug Research\u003cbr\u003e \u003cbr\u003e \"Dem Herausgeber ist mit diesem Werk gelungen, das gesamte Spektrum der Biopharmazeutika umfassend abzudecken, weshalb man heute vom \"Guiness-Buch der Biotechnologie\" spricht.\"\u003cbr\u003e Pharmazie in unserer Zeit\u003cbr\u003e Dr. Jorg Knablein studied Biotechnology \/ Chemical Engineering at the Society for Biotechnology Research (GBF) in Braunschweig, Germany and Biochemistry at the Max-Planck-Institute for Biochemistry. He received his Ph.D. from the Max-Planck-Institute for Biochemistry in Martinsried \/ Munich where he worked in the group of Professor Huber (Nobelprize laureate in 1988).\u003cbr\u003e \u003cbr\u003e AWARDS:\u003cbr\u003e Riedel-de Haen-Stiftung\u003cbr\u003e Government \/ Ministry of Science\u003cbr\u003e Nomination for the Max-Buchner-Award from DECHEMA (Society for Biotechnology and Chemical Engineering)\u003cbr\u003e Winner of the McKinsey business plan contest The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 120 such products are currently being marketed around the world, including nine blockbuster drugs, and nowadays represent the mainstay products of the biotechnology industry. \u003cbr\u003e This book is unique in introducing readers to a comprehensive set of recently developed technologies, showing paradigm shifts in the health care system and reflecting these changes in industrial research.\u003cbr\u003e Here, the world's top scientists and business leaders divulge their first-hand expertise, allowing you to participate in their recent achievements. They all have their own specific contribution and have been carefully selected to provide a multifaceted and unique insight. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel laureates Robert Huber and Thomas R. Cech, as well as authors from the world's most famous academic institutes and biotech companies, such as ETH Zurich, MIT, Stanford, Yale, Princeton, Harvard Medical School, Max-Planck-Institute, Fraunhofer-Institute, Moscow Academy of Sciences, London Imperial College and Baxter, Invitrogen, MorphoSys, Roche, and Schering AG.\u003cbr\u003e The result is a testament to the importance of biotechnology in life science, a sure sign that \"Modern Biopharmaceuticals\" will fuel biotechnologies and help shape the industry of the future.\u003cbr\u003e For pharmaceutists, pharmaceutical chemists, biochemists, molecular biologists, medicinal chemists, as well as those working in the biotechnological and pharmaceutical industries, or biotechnological institutes.","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989639971045,"sku":"NP9783527311842","price":1023.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9783527311842.jpg?v=1761784917","url":"https:\/\/k12savings.com\/products\/modern-biopharmaceuticals-4-volume-set-isbn-9783527311842","provider":"K12savings","version":"1.0","type":"link"}